This indicates that the inhibition of FXR may sensitize the immunotherapy with anit-PD1/PD-L1 antibodies, since PD-L1 expression is a predictive biomarker for immunotherapy in NSCLC patients. Here, NR1H4 is linked to non-small cell lung carcinoma.